1 Introduction
==============

PubMed contains over 30 million publications and is growing rapidly. Accurate, automated text mining tools are needed to maximize discovery and unlock structured information from this massive volume of text ([@btz504-B7]; [@btz504-B27]). Biomedical named entity recognition (BioNER) is the task of identifying biomedical named entities---such as genes and gene products, diseases, chemicals and species---in raw text. Biomedical named entities have several characteristics that make their recognition in text challenging ([@btz504-B34]), including the use of descriptive entity names (e.g. 'normal thymic epithelial cells') leading to ambiguous term boundaries, and several spelling forms for the same entity (e.g. '*N*-acetylcysteine', '*N*-acetyl-cysteine' and 'NAcetylCysteine'). Many solutions for reliable BioNER have been proposed (e.g. [@btz504-B9]; [@btz504-B18]) and current state-of-the-art approaches employ a domain-independent approach, based on deep learning and statistical word embeddings, called bidirectional long short-term memory network-conditional random field (BiLSTM-CRF; [@btz504-B14]; [@btz504-B19]; [@btz504-B22]) or modifications to this approach \[e.g. transfer learning ([@btz504-B13]) and multi-task learning ([@btz504-B31])\].

While BiLSTM-CRF paired with pre-trained word embeddings as inputs is a powerful approach to sequence labeling ([@btz504-B16]), it has many trainable parameters which could lead to a reduction in generalizability. Here, we are concerned with the ability of a model to generalize from training on one corpus to testing on another for the same biomedical entity. This simulates a real-world scenario where the model is used to annotate text which is outside the corpus it was trained on, but still within the biomedical domain. Generalization across biomedical corpora appears to be a problem even for less-parameterized machine learning methods. For example, Gimli, an open-source tool for BioNER based on a CRF classifier, achieved an *F*~1~ score of 87.17% when trained and tested on the GENETAG corpus ([@btz504-B3]), but only a 45--55% *F*~1~ score when trained on the GENETAG corpus and tested on the CRAFT corpus for genes and proteins ([@btz504-B4]). [@btz504-B12] explore this further by demonstrating that performance of a CRF model for BioNER trained on individual corpora decreases substantially for recognition of the same biomedical entity in independent corpora. They conclude that bias in the available BioNER evaluation corpora is partly to blame. In a simple orthographic feature analysis (i.e. what does a word look like?), they find that features which significantly predict biomedical named entities in one corpus (e.g. number of digits or capital letters, text span length) are not necessarily useful to predict those same entities in a different corpus. We need to address this problem if BiLSTM-CRF models are to be useful in real-world scenarios involving the large-scale annotation of diverse articles.

To address this challenge, we evaluate successful ideas from recent work on BiLSTM-CRF models for BioNER ([@btz504-B13]; [@btz504-B14]; [@btz504-B31]) and sequence labeling with BiLSTM-CRFs in general ([@btz504-B26]) and propose several model-based strategies to improve generalization, namely: additional regularization via variational dropout, transfer learning and multi-task learning. We assessed the performance of the model on the same corpus it was trained on ('in-corpus' performance) and when trained on one corpus and tested on another corpus annotated for the same entity class ('out-of-corpus' performance). All proposed strategies achieved an improvement in out-of-corpus performance without degrading the average in-corpus performance. The best improvement resulted from a combination of multi-task learning and variational dropout, which boosts out-of-corpus performance by 10.75%. We make available to the community a user-friendly, open-source tool for BioNLP ('Saber') which incorporates these successful model features (<https://github.com/BaderLab/saber>).

2 Materials and methods
=======================

We evaluated three modifications to a BiLSTM-CRF model's architecture and training strategy aimed at improving generalization, described briefly below (details in [Supplementary Material](#sup1){ref-type="supplementary-material"}). We use the BiLSTM-CRF neural network architecture introduced by [@btz504-B19] as our baseline (BL) model ([Supplementary Fig. S1](#sup1){ref-type="supplementary-material"}).

2.1 Variational dropout
-----------------------

As neural networks have many parameters, model regularization is critical for generalization performance. Traditionally, the 'dropout' technique, which randomly drops units during training, is used for this purpose ([@btz504-B29]). Previous applications of BiLSTM-CRF models for BioNER ([@btz504-B13]; [@btz504-B14]) have only applied dropout to the character-enhanced word embeddings, the final inputs to the word-level BiLSTM layers, as originally proposed by [@btz504-B19]. However, no regularization technique is applied to the recurrent layers of the model, which contain the majority of the model's trainable parameters. Part of the reason for this is likely that the standard dropout implementation is ineffective for regularizing recurrent connections, as it disrupts the recurrent neural networks ability to retain long-term dependencies ([@btz504-B2]; [@btz504-B23]; [@btz504-B33]). Variational dropout, where the same units are dropped across multiple time steps (in our case, tokens of an input sentence), has been proposed to overcome this ([@btz504-B11]) ([Supplementary Fig. S2](#sup1){ref-type="supplementary-material"}). We hypothesize that regularizing the recurrent layers of the BiLSTM-CRF model via variational dropout will improve out-of-corpus generalization. To test this, we compare the performance of two BiLSTM-CRF models for the task of BioNER: one with the standard dropout strategy ([@btz504-B13]; [@btz504-B14]; [@btz504-B19]), and a second where variational dropout is additionally applied to the input, recurrent and output connections of all recurrent layers.

2.2 Transfer learning
---------------------

Transfer learning is a machine learning research problem which aims to perform a task on a 'target' dataset using knowledge learned from a 'source' dataset ([@btz504-B21]; [@btz504-B24]; [@btz504-B32]). Ideally, transfer learning reduces training time on the target dataset and the amount of labeled data needed to obtain high performance. It can be used to improve model generalization by training on very large, but usually lower quality silver standard corpus (SSC), and then using the learned parameters to initialize training on a smaller, manually generated and more reliable gold-standard corpus (GSC). We recently showed that transfer learning for BioNER ([@btz504-B13]) reduces the amount of labeled data needed to achieve high performance from a BiLSTM-CRF model, but we did not assess its impact on generalizability. As in [@btz504-B13], here we apply transfer learning by first training on a large, semi-automatically generated and lower quality SSC and then transfer to continued training on a GSC. Like [@btz504-B13], we use CALBC-SSC-III (Collaborative Annotation of a Large Biomedical Corpus) as our SSC ([@btz504-B17]; [@btz504-B25]).

2.3 Multi-task learning
-----------------------

Multi-task learning ([@btz504-B5]) is a machine learning method in which multiple learning tasks are solved at the same time. The idea is that by sharing representations between tasks, we can exploit commonalities, leading to improved learning efficiency, prediction accuracy and generalizability for the task-specific models, when compared to training the models separately ([@btz504-B1]; [@btz504-B6]; [@btz504-B30]). Recently, [@btz504-B8] demonstrated that a neural network multi-task convolutional neural network (CNN) model outperforms a comparable single-task model, on average, for the task of BioNER. Similarly, [@btz504-B31] found that multi-task learning outperforms single-task learning for BioNER with a BiLSTM-CRF. Neither study explored the effect of multi-task learning on the model's ability to generalize across corpora. We hypothesize that multi-task learning will improve across-corpora generalization, potentially as a result of exposing the model to more training data. To test this, we compare the performance of a single-task and multi-task BiLSTM-CRF model for the task of BioNER.

Our multi-task model (MTM) builds off this BiLSTM-CRF architecture. The MTM is a global model comprised of distinct, task-specific input and output layers, while the hidden layers (and their parameters) are shared across all tasks ([Supplementary Fig. S3](#sup1){ref-type="supplementary-material"}). We follow [@btz504-B31] who found it best to share all hidden layers of the BiLSTM-CRF model for BioNER. During training, all corpora are used to update the parameters of the hidden layers of the model but the output 'task' layers are trained using only their corresponding corpus. In our multi-task experiments, two corpora of the same entity type are used to train the model. The 'train' corpus is used to train the output layer that is then evaluated on the 'test' corpus. The 'partner' corpus contributes to hidden layer training and is used to train its output layer, but the corresponding output is not used for performance evaluation. During training, the model optimizes the log-probability of the correct tag sequence for each corpus. In practice, the model is trained in an end-to-end fashion.

3 Results
=========

3.1 Establishing a baseline
---------------------------

To establish a baseline for each corpus used in this study, we performed 5-fold cross-validation using the hyperparameters presented in [Supplementary Material](#sup1){ref-type="supplementary-material"}, Section 3.5. We use the dropout strategy proposed by [@btz504-B19] and employed by [@btz504-B14] and [@btz504-B13], which applies a single dropout layer (with a dropout rate of 0.3) to the character-enhanced word embeddings, which is the final input to the word-level BiLSTM layers. In [Supplementary Table S3](#sup1){ref-type="supplementary-material"}, we present our baseline *F*~1~ scores along with the best reported *F*~1~ scores from [@btz504-B14], [@btz504-B31] and [@btz504-B13], all of whom use nearly identical BiLSTM-CRF models and the same word embeddings as used in this study, and [@btz504-B8], who used a CNN-based model for BioNER. Our baseline significantly outperforms previous results obtained with BiLSTM-CRF models for 7 out of the 12 corpora evaluated and was comparable to the best method in the remaining 5 cases. Since our architecture is nearly identical and paired with the same word embeddings, this is likely due to our hyperparameter choice as presented by [@btz504-B26]. For the remainder of the study, we compare all performance scores to our baseline.

3.2 Can BiLSTM-CRF generalize for BioNER?
-----------------------------------------

To test the out-of-corpus generalizability of a BiLSTM-CRF model for BioNER, we trained the model on various corpora and evaluated its performance on independent corpora annotated for the same entity type. Even when corpora are annotated for the same entity type, they may have different biases, given that they are typically independently developed with different annotation guidelines. To control for the expected drop in performance due to differing annotation guidelines, we used a relaxed matching criterion in our evaluation (described in [Supplementary Material](#sup1){ref-type="supplementary-material"}, Section 3.7). We found that, even with a relaxed matching criterion, performance of the model as measured by *F*~1~ score falls by an average of 31.16% when the model is evaluated on a corpus other than the one it was trained on ([Supplementary Table S4](#sup1){ref-type="supplementary-material"}). Out-of-corpus performance was worst for chemicals, falling by an average of 33.45%, followed by genes/proteins (29.27%), species (28.47%) and disease (26.09%). These results demonstrate the dramatically poor out-of-corpus generalizability of BiLSTM-CRF for BioNER, even though the model obtains state-of-the-art results when trained and tested on the same corpus ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}).

3.3 Improved regularization
---------------------------

We next explored the effect that additional regularization of the BiLSTM-CRF model via variational dropout (see Section 2.1) has on both in-corpus and out-of-corpus performance. In [Table 1](#btz504-T1){ref-type="table"}, we compare the in-corpus performance of the baseline (BL) BiLSTM-CRF model employing a simple dropout strategy---proposed by [@btz504-B19] and used in previous applications of BiLSTM-CRF to BioNER ([@btz504-B13]; [@btz504-B14])---compared to a model in which variational dropout has been additionally applied to the recurrent layers. We use dropout ratios of 0.3, 0.3 and 0.1 for the input, output and recurrent connections, respectively. In [Table 2](#btz504-T2){ref-type="table"}, we measure the effect that variational dropout has on the generalizability of the model, by comparing out-of-corpus performance to the baseline.

###### 

In-corpus (IC) performance, measured by *F*~1~-score, of the baseline (BL) BiLSTM-CRF compared to a BiLSTM-CRF with variational dropout (VD)

                                  BL          VD                                                      
  ---------------- -------------- ----------- ------ ------------------------------------------------ ------
  Chemicals        BC4CHEMD       88.46       0.61   **88.71**                                        0.76
                   BC5CDR         92.82       0.80   **93.08**                                        0.82
                   CRAFT          84.98       1.98   **85.22**                                        1.37
  Disease          BC5CDR         84.49       0.33   **85.10**                                        0.56
                   NCBI-disease   87.01       1.17   **87.60**                                        1.50
                   Variome        **85.75**   2.83   85.69                                            3.81
  Species          CRAFT          96.28       2.21   **96.38**                                        2.26
                   Linnaeus       89.44       3.91   **89.66**                                        7.47
                   S800           72.75       2.42   **77.39**                                        4.17
  Genes/proteins   BC2GM          81.48       0.48   **83.10** [\*\*](#tblfn2){ref-type="table-fn"}   0.50
                   CRAFT          84.46       6.08   **86.09**                                        5.19
                   JNLPBA         80.92       2.50   **81.95**                                        2.62

*Note*: In the BL model, dropout is applied only to the character-enhanced word embeddings. In the VD model, dropout is additionally applied to the input, recurrent and output connections of all LSTM layers. IC performance is derived from 5-fold cross-validation, using exact matching criteria. Statistical significance is measured through a two-tailed *t*-test. Bold, best scores, σ, standard deviation.

Significantly different than the BL (*P* ≤ 0.01).

###### 

Out-of-corpus (OOC) performance, measured by *F*~1~ score, of the baseline (BL) BiLSTM-CRF compared to a BiLSTM-CRF with variational dropout (VD)

  Entity           Train          Test           BL          VD                                               $\Delta F_{1}$
  ---------------- -------------- -------------- ----------- ------------------------------------------------ ----------------
  Chemicals        BC4CHEMD       BC5CDR         **90.90**   90.61                                            −0.29
                                  CRAFT          47.44       **47.67**                                        0.23
                   BC5CDR         BC4CHEMD       71.81       **72.41**                                        0.60
                                  CRAFT          39.55       **41.30** [\*\*](#tblfn5){ref-type="table-fn"}   1.74
                   CRAFT          BC4CHEMD       40.50       **42.65**                                        2.14
                                  BC5CDR         41.59       **56.64** [\*\*](#tblfn5){ref-type="table-fn"}   15.05
  Diseases         BC5CDR         NCBI-disease   76.67       **80.86** [\*](#tblfn4){ref-type="table-fn"}     4.19
                                  Variome        74.03       **74.83**                                        0.81
                   NCBI-disease   BC5CDR         69.62       **74.96** [\*\*](#tblfn5){ref-type="table-fn"}   5.33
                                  Variome        74.98       **75.69**                                        0.72
                   Variome        BC5CDR         22.45       **30.38** [\*](#tblfn4){ref-type="table-fn"}     7.93
                                  NCBI-disease   40.17       **45.16** [\*\*](#tblfn5){ref-type="table-fn"}   4.99
  Species          CRAFT          Linnaeus       45.32       **53.25** [\*](#tblfn4){ref-type="table-fn"}     7.93
                                  S800           36.88       **46.10** [\*\*](#tblfn5){ref-type="table-fn"}   9.21
                   Linnaeus       CRAFT          82.49       **82.85**                                        0.36
                                  S800           62.90       **66.93** [\*](#tblfn4){ref-type="table-fn"}     4.02
                   S800           CRAFT          57.09       **76.44** [\*\*](#tblfn5){ref-type="table-fn"}   19.34
                                  Linnaeus       61.43       **67.05** [\*](#tblfn4){ref-type="table-fn"}     5.62
  Genes/proteins   BC2GM          CRAFT          56.04       **58.17**                                        2.12
                                  JNLPBA         69.77       **70.79** [\*\*](#tblfn5){ref-type="table-fn"}   1.02
                   CRAFT          BC2GM          44.11       **49.12** [\*](#tblfn4){ref-type="table-fn"}     5.01
                                  JNLPBA         52.88       **56.30**                                        3.42
                   JNLPBA         BC2GM          51.03       **55.61**                                        4.57
                                  CRAFT          44.29       **49.08**                                        4.79

*Note*: In the BL model, dropout is applied only to the character-enhanced word embeddings. In the VD model, dropout is additionally applied to the input, recurrent and output connections of all LSTM layers. OOC performance is derived by training on one corpus (train) and testing on another annotated for the same entity type (test) using a relaxed, right-boundary matching criteria. Bold, best scores.

Significantly different than the BL (*P* ≤ 0.05).

Significantly different than the BL (*P* ≤ 0.01).

In general, variational dropout has a small positive impact on in-corpus performance. For at least two corpora, S800 and BC2GM, variational dropout leads to a large improvement in performance, but only the latter case is statistically significant. For out-of-corpus performance, variational dropout improves performance for nearly every train/test corpus pair we evaluated, with an average *F*~1~ score improvement of 4.62%. In some cases, variational dropout leads to sizable improvements in out-of-corpus performance, such as when the model was trained on S800 and tested on CRAFT (19.34%), or trained on CRAFT and tested on BC5CDR (15.05%). In one case---when trained to recognize chemicals on BC4CHEMD and tested on BC5CDR---variational dropout reduced out-of-corpus performance, although the performance difference was minimal (\<0.5%). Thus, variational dropout improves the out-of-corpus performance of the model, without degrading in-corpus performance. Regularization of the recurrent layers of a BiLSTM-CRF model via variational dropout, therefore, can improve model generalizability for BioNER.

3.4 Transfer learning
---------------------

In this experiment, we measure the effect that a transfer learning strategy for BiLSTM-CRF has on both in-corpus and out-of-corpus performance. In [Table 3](#btz504-T3){ref-type="table"}, we compare the in-corpus performance of the baseline BiLSTM-CRF model (BL) to that of the model trained with transfer learning and in [Table 4](#btz504-T4){ref-type="table"} we similarly compare out-of-corpus performance of the two models. In the transfer learning setting, the model was pre-trained on the CALBC-SSC-III corpus, which is annotated for chemicals, diseases, species and genes/proteins, before being trained on one of the 12 GSCs, each annotated for a single entity class. The state of the optimizer is reset during this transfer, but model weights for all layers beside the final CRF layer are retained (see Section 2.2 and [Supplementary Material](#sup1){ref-type="supplementary-material"}, Section 3.5).

###### 

In-corpus (IC) performance, measured by *F*~1~-score, of the baseline (BL) BiLSTM-CRF compared to a BiLSTM-CRF trained with transfer learning (TL)

                                  BL            TL                                             
  ---------------- -------------- ----------- ------ ----------------------------------------- ------
  Chemicals        BC4CHEMD       88.46        0.61  **88.98**                                  0.63
                   BC5CDR         **92.82**    0.80  92.20                                      0.86
                   CRAFT          84.98        1.98  **85.80**                                  1.74
  Disease          BC5CDR         **84.49**    0.33  84.41                                      0.24
                   NCBI-disease   87.01        1.17  **87.66**                                  0.86
                   Variome        85.75        2.83  **86.69**                                  3.03
  Species          CRAFT          96.28        2.21  **96.55**                                  1.72
                   Linnaeus       89.44        3.91  **90.72**                                  4.90
                   S800           72.75        2.42  **74.93**                                  3.27
  Genes/proteins   BC2GM          **81.48**    0.48  80.65[\*](#tblfn7){ref-type="table-fn"}    0.57
                   CRAFT          84.46        6.08  **85.50**                                  4.59
                   JNLPBA         80.92        2.50  **81.56**                                  2.73

*Note*: The TL model was pre-trained on the CALBC-Small-III corpus. IC performance is derived from 5-fold cross-validation, using exact matching criteria. Statistical significance is measured through a two-tailed *t*-test. Bold, best scores, σ, standard deviation.

Significantly different than the BL (*P* ≤ 0.05).

###### 

Out-of-corpus (OOC) performance, measured by *F*~1~ score, of the baseline (BL) BiLSTM-CRF compared to a BiLSTM-CRF trained with transfer learning (TL)

  Entity           Train          Test           BL          TL                                                $\Delta F_{1}$
  ---------------- -------------- -------------- ----------- ------------------------------------------------- ----------------
  Chemicals        BC4CHEMD       BC5CDR         **90.90**   90.73                                             −0.17
                                  CRAFT          **47.44**   47.02                                             −0.42
                   BC5CDR         BC4CHEMD       71.81       **74.27** [\*](#tblfn9){ref-type="table-fn"}      2.46
                                  CRAFT          39.55       **41.20** [\*](#tblfn9){ref-type="table-fn"}      1.64
                   CRAFT          BC4CHEMD       40.50       **46.15** [\*](#tblfn9){ref-type="table-fn"}      5.64
                                  BC5CDR         41.59       **58.57** [\*\*](#tblfn10){ref-type="table-fn"}   16.98
  Diseases         BC5CDR         NCBI-disease   76.67       **78.51** [\*](#tblfn9){ref-type="table-fn"}      1.83
                                  Variome        74.03       **77.18**                                         3.16
                   NCBI-disease   BC5CDR         69.62       **73.19**                                         3.56
                                  Variome        74.98       **76.95** [\*](#tblfn9){ref-type="table-fn"}      1.97
                   Variome        BC5CDR         22.45       **50.28** [\*\*](#tblfn10){ref-type="table-fn"}   27.83
                                  NCBI-disease   40.17       **58.64** [\*\*](#tblfn10){ref-type="table-fn"}   18.47
  Species          CRAFT          Linnaeus       45.32       **53.37**                                         8.04
                                  S800           36.88       **46.46** [\*\*](#tblfn10){ref-type="table-fn"}   9.57
                   Linnaeus       CRAFT          82.49       **83.07**                                         0.57
                                  S800           62.90       **67.64** [\*](#tblfn9){ref-type="table-fn"}      4.73
                   S800           CRAFT          57.09       **69.56** [\*\*](#tblfn10){ref-type="table-fn"}   12.47
                                  Linnaeus       61.43       **67.21** [\*](#tblfn9){ref-type="table-fn"}      5.78
  Genes/proteins   BC2GM          CRAFT          56.04       **56.84**                                         0.79
                                  JNLPBA         69.77       **70.27**                                         0.50
                   CRAFT          BC2GM          44.11       **49.69** [\*](#tblfn9){ref-type="table-fn"}      5.58
                                  JNLPBA         52.88       **57.91** [\*](#tblfn9){ref-type="table-fn"}      5.03
                   JNLPBA         BC2GM          51.03       **57.81** [\*](#tblfn9){ref-type="table-fn"}      6.78
                                  CRAFT          44.29       **56.90** [\*\*](#tblfn10){ref-type="table-fn"}   12.61

*Note*: The TL model was pre-trained on the CALBC-Small-III corpus. OOC performance is derived by training on one corpus (train) and testing on another annotated for the same entity type (test) using a relaxed, right-boundary matching criteria. Statistical significance is measured through a two-tailed *t*-test. Bold, best scores.

Significantly different than the BL (*P* ≤ 0.05).

Significantly different than the BL (*P* ≤ 0.01).

In general, transfer learning had a small positive effect on in-corpus performance, boosting the average *F*~1~ score by ∼1%. In contrast, transfer learning had a large positive effect on out-of-corpus performance, improving performance for nearly every train/test pair we evaluated for an average improvement of 6.48%. In a handful of cases, such as when the model was trained on the CRAFT corpus and tested on the BC5CDR corpus, performance improved by over 10%. In a single case (i.e. when the model was trained on Variome and tested on BC5CDR) transfer learning doubled out-of-corpus performance over the baseline. Thus, the use of transfer learning improves the generalizability of BiLSTM-CRF models for BioNER, in some cases dramatically, while preserving in-corpus performance.

3.5 Multi-task learning
-----------------------

To assess the effect that a multi-task learning strategy for BiLSTM-CRF has on both in-corpus and out-of-corpus performance, we evaluate a model trained on all corpus pairs within an entity class. Each model is simultaneously trained on a 'train' and 'partner' corpus, each defined as a separate task, and a 'test' corpus is used to evaluate performance on the 'train' task (see Section 2.3 and [Supplementary Material](#sup1){ref-type="supplementary-material"}, Section 3.5). In [Table 5](#btz504-T5){ref-type="table"} we compare the in-corpus performance of the single-task, baseline BiLSTM-CRF model, to that of the MTM. In [Table 6](#btz504-T6){ref-type="table"} we similarly compare out-of-corpus performance of the BL and MTM.

###### 

In-corpus (IC) performance, measured by *F*~1~-score, of the baseline (BL) BiLSTM-CRF compared to the multi-task model (MTM)

                                                     BL       MTM                                                
  ---------------- -------------- -------------- ----------- ------ -------------------------------------------- ------
  Chemicals        BC4CH.         BC5CDR            88.46     0.61  **88.81**                                     0.60
                                  CRAFT              ---      ---   88.67                                         0.50
                   BC5CDR         BC4CH.            92.82     0.80  **93.00**                                     0.55
                                  CRAFT              ---      ---   91.52[\*](#tblfn12){ref-type="table-fn"}      0.68
                   CRAFT          BC4CH.            84.98     1.98  **85.06**                                     1.49
                                  BC5CDR             ---      ---   84.74                                         1.33
  Diseases         BC5CDR         NCBI-disease    **84.49**   0.33  83.85                                         0.64
                                  Variome            ---      ---   83.29[\*](#tblfn12){ref-type="table-fn"}      0.80
                   NCBI-disease   BC5CDR          **87.01**   1.17  86.89                                         1.74
                                  Variome            ---      ---   86.27                                         1.44
                   Variome        BC5CDR            85.75     2.83  **86.13**                                     2.49
                                  NCBI-disease       ---      ---   85.73                                         2.46
  Species          CRAFT          Linnaeus          96.28     2.21  96.82                                         1.51
                                  S800               ---      ---   **96.90**                                     1.31
                   Linnaeus       CRAFT             89.44     3.91  89.72                                         4.51
                                  S800               ---      ---   **92.18**                                     3.42
                   S800           CRAFT             72.75     2.42  **74.80**                                     2.98
                                  Linnaeus           ---      ---   74.43                                         1.90
  Genes/proteins   BC2GM          CRAFT           **81.48**   0.48  79.41[\*\*](#tblfn13){ref-type="table-fn"}    0.14
                                  JNLPBA             ---      ---   79.60[\*\*](#tblfn13){ref-type="table-fn"}    0.53
                   CRAFT          BC2GM             84.46     6.08  **87.76**                                     2.65
                                  JNLPBA             ---      ---   85.36                                         4.74
                   JNLPBA         BC2GM             80.92     2.50  **81.61**                                     2.53
                                  CRAFT              ---      ---   81.15                                         2.04

*Note*: The MTM is trained on pairs of corpora (train, partner), where each corpus is used during training to update the parameters of all hidden layers. IC performance is derived from 5-fold cross-validation, using exact matching criteria. Statistical significance is measured through a two-tailed *t*-test. Bold, best scores, σ, standard deviation.

Significantly different than the BL (*P* ≤ 0.05).

Significantly different than the BL (*P* ≤ 0.01).

###### 

Out-of-corpus (OOC) performance, measured by *F*~1~ score, of the baseline (BL) BiLSTM-CRF compared to the multi-task model (MTM)

  Entity           Train          Partner        Test           BL      MTM                                               $\Delta F_{1}$
  ---------------- -------------- -------------- -------------- ------- ------------------------------------------------- ----------------
  Chemicals        BC4CHEMD       BC5CDR         CRAFT          47.44   **47.74**                                         0.29
                                  CRAFT          BC5CDR         90.90   **90.97**                                         0.07
                   BC5CDR         BC4CHEMD       CRAFT          39.55   **44.79** [\*\*](#tblfn16){ref-type="table-fn"}   5.24
                                  CRAFT          BC4CHEMD       71.81   **72.54**                                         0.73
                   CRAFT          BC4CHEMD       BC5CDR         41.59   **71.68** [\*\*](#tblfn16){ref-type="table-fn"}   30.09
                                  BC5CDR         BC4CHEMD       40.50   **49.80** [\*\*](#tblfn16){ref-type="table-fn"}   9.30
  Diseases         BC5CDR         NCBI-disease   Variome        74.03   **76.84** [\*](#tblfn15){ref-type="table-fn"}     2.81
                                  Variome        NCBI-disease   76.67   **77.33**                                         0.66
                   NCBI-disease   BC5CDR         Variome        74.98   **76.32** [\*](#tblfn15){ref-type="table-fn"}     1.34
                                  Variome        BC5CDR         69.62   **70.72**                                         1.10
                   Variome        BC5CDR         NCBI-disease   40.17   **69.35** [\*\*](#tblfn16){ref-type="table-fn"}   29.18
                                  NCBI-disease   BC5CDR         22.45   **60.06** [\*\*](#tblfn16){ref-type="table-fn"}   37.61
  Species          CRAFT          Linnaeus       S800           36.88   **50.26**                                         13.38
                                  S800           Linnaeus       45.32   **57.80** [\*\*](#tblfn16){ref-type="table-fn"}   12.48
                   Linnaeus       CRAFT          S800           62.90   **67.90**                                         4.99
                                  S800           CRAFT          82.49   **82.69**                                         0.20
                   S800           CRAFT          Linnaeus       61.43   **67.90** [\*\*](#tblfn16){ref-type="table-fn"}   6.46
                                  Linnaeus       CRAFT          57.09   **80.04** [\*\*](#tblfn16){ref-type="table-fn"}   22.94
  Genes/proteins   BC2GM          CRAFT          JNLPBA         69.77   **70.26**                                         0.49
                                  JNLPBA         CRAFT          56.04   **57.17**                                         1.12
                   CRAFT          BC2GM          JNLPBA         52.88   **58.78** [\*](#tblfn15){ref-type="table-fn"}     5.89
                                  JNLPBA         BC2GM          44.11   **45.12**                                         1.01
                   JNLPBA         BC2GM          CRAFT          44.29   **52.78** [\*](#tblfn15){ref-type="table-fn"}     8.49
                                  CRAFT          BC2GM          51.03   **57.35** [\*\*](#tblfn16){ref-type="table-fn"}   6.32

*Note*: The MTM is trained on pairs of corpora (train, partner), where each corpus is used during training to update the parameters of all hidden layers, but only the train corpus task is used for evaluation on another corpus annotated for the same entity type (test) using a relaxed, right-boundary matching criteria. Bold, best scores.

Significantly different than the BL (*P* ≤ 0.05).

Significantly different than the BL (*P* ≤ 0.01).

Multi-task learning, as applied here, appears to have little impact on in-corpus performance. Average performance of the BL and the MTM were nearly identical, at 85.74 and 85.99% respectively, though in a few cases, such as when the model was trained on BC2GM alongside CRAFT or JNLPBA, the MTM significantly underperforms the baseline. On the other hand, multi-task learning improved out-of-corpus performance for every train/partner/test corpus set we evaluated, with an average improvement of 8.42%. In some cases, this improvement was substantial, such as when the model was trained on the Variome and NCBI-Disease corpora and tested on the BC5CDR corpus (37.61%). However, we do observe significant variability overall in the degree of improvement, suggesting that multi-task learning is sensitive to the choice of train/partner pairs. Thus, a multi-task learning strategy of simultaneously training on multiple corpora can substantially boost out-of-corpus performance of BiLSTM-CRF models for BioNER.

3.6 Combining modifications
---------------------------

We next evaluate if combinations of the above modifications improve BiLSTM-CRFs model performance above individual modifications ([Fig. 1](#btz504-F1){ref-type="fig"}). In general, all combinations of the proposed modifications improve average out-of-corpus performance without degrading in-corpus performance. However, not all combinations are additive. For example, multi-task learning improves out-of-corpus performance by 8.42%, transfer learning by 6.48% but together only by 5.61%. The biggest boost to out-of-corpus performance is achieved by the MTM paired with additional regularization of the recurrent layers via variational dropout, improving average performance by 10.75%. Therefore, we recommend using this combination to produce a model with the highest expected out-of-corpus performance.

![Violin plot of the average in-corpus (IC) and out-of-corpus (OOC) performance, measured by *F*~1~ score, of the BiLSTM-CRF model. IC performance is derived from 5-fold cross-validation, using exact matching criteria. OOC performance is derived by training on one corpus (train) and testing on another corpus annotated for the same entity type (test) using a relaxed, right-boundary matching criterion. The average performance of a model employing one of each of the proposed modifications: variational dropout (VD), transfer learning (TL) and multi-task learning (MTL) independently as well as models which employ all combinations of these methods are shown](btz504f1){#btz504-F1}

4 Discussion
============

We demonstrate that BiLSTM-CRF, a popular deep learning-based approach to BioNER and sequence labeling in general, does a poor job generalizing to corpora other than the one it was trained on. While some drop in performance is expected whenever a model is evaluated on data outside the train set, the magnitude of decrease we observed was substantial, falling by an average of over 30% *F*~1~ score. This was true even though we used a liberal scoring criterion and any two corpora in our experiments were annotated for the same entity type (and sometimes even used similar annotator guidelines, such as the case with BC5CDR and NCBI-Disease).

There are two possible explanations for the poor out-of-corpus generalization we observed---either the corpora are biased or insufficient or the model is prone to training in a corpora specific manner. Likely both reasons contribute to the problem. We elected to explore improving the model because corpus creation is extremely laborious and modification of existing corpora would make it difficult to compare our methods against existing solutions. The three modifications we evaluated---variational dropout, transfer learning and multi-task learning---are straightforward to implement and improve across-corpora generalizability without degrading average in-corpus performance. On average, variational dropout improves out-of-corpus performance by 4.62%, transfer learning by 6.48% and multi-task learning by 8.42%, and the best combination of these (multi-task learning and variational dropout) improves average out-of-corpus performance by 10.75%. We provide our model to the community as an easy-to-use tool for BioNLP under a permissive MIT license (<https://github.com/BaderLab/saber>).

We note three limitations of our work. First, the most promising modification to BiLSTM-CRF, multi-task learning, appears to be sensitive to the choice of train/partner corpus pairs. A user should, therefore, evaluate multiple train/partner corpora to determine the most beneficial combination for their use case. Second, while transfer learning is not part of our recommended combination, we previously found it to significantly improve performance on smaller corpora (\<6000 labels) ([@btz504-B13]). While we did not evaluate the effect of corpus size, presumably, transfer learning would still be useful and should be considered for small corpora. Third, in our multi-task experiments, we restricted ourselves to training only on two corpora, which were annotated for the same entity type. These restrictions were made only to keep the number and the training time of the multi-task experiments within a reasonable range and not because of inherent limitations in the model's architecture. Previous work has suggested that multi-task learning with deep neural networks for the task of BioNER may increase performance even when trained on corpora that do not annotate the same entity class. [@btz504-B8] report, for example, that the best partner for Linnaeus (Species) out of 15 corpora was NCBI-Disease (Disease), not another Species corpus. Additionally, previous work ([@btz504-B31]) has suggested that training a BiLSTM-CRF on many corpora (i.e. \>2) in a multi-task setting leads to sizable improvements in BioNER. Thus, a further direction for our work could be to explore performance improvements as increasing numbers of corpora annotated for different entity types are used for training. We suspect that this could significantly boost out-of-corpus performance. Further, these results suggest that a single model trained on many corpora (and even additionally pre-trained on an extremely large SSC) may produce a robust and reliable tagger suitable for deployment on massive literature databases (such as PubMed).

Our strategy for transfer learning involves pre-training a model on a large SSC and transferring the learned weights to initialize training on a smaller, but typically much higher quality, GSC. As we were writing this paper, a novel transfer learning strategy for NLP demonstrated state-of-the-art performance on many benchmark corpora (<https://s3-us-west-2.amazonaws.com/openai-assets/research-covers/language-unsupervised/language_understanding_paper.pdf>; [@btz504-B10]; [@btz504-B15]). This transfer learning strategy involves first training a language model on a massive corpus of unlabeled text. The task of a language model is to predict the next most probable word given a sequence of words (or more recently, to predict randomly masked words). By learning this task, the model is required to capture both syntax and semantics and is also required to encode something akin to common sense. This is followed by the addition of task-specific layers, which take the output of the language model as input and are trained on labeled data in order for the model to learn a specific classification task such as NER. This transfer learning strategy has already been applied to BioNER with some success ([@btz504-B20]; [@btz504-B28]). In the future, we plan to explore this transfer learning strategy for BioNER, and also for other tasks in the biomedical text mining pipeline, such as relation and event extraction.

5 Conclusion
============

While BioNER has recently made substantial advances in performance with the application of deep learning, current applications suffer from poor generalizability in real-world scenarios. We show that out-of-corpus performance of a BiLSTM-CRF model for BioNER (training on one corpus and testing on another annotated for the same entity type) suffers when using a current state-of-the-art model. Straightforward model modifications (variational dropout, transfer learning, and multi-task learning and their combinations) substantially improve across-corpora generalization performance. We propose that our model will significantly outperform previous applications of BiLSTM-CRF models to BioNER when deployed for the large-scale annotation of widely diverse articles, such as the articles found in databases like PubMed. We make our model accessible as an easy-to-use BioNLP tool, Saber (<https://github.com/BaderLab/saber>).
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